MX2021002109A - Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer. - Google Patents
Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.Info
- Publication number
- MX2021002109A MX2021002109A MX2021002109A MX2021002109A MX2021002109A MX 2021002109 A MX2021002109 A MX 2021002109A MX 2021002109 A MX2021002109 A MX 2021002109A MX 2021002109 A MX2021002109 A MX 2021002109A MX 2021002109 A MX2021002109 A MX 2021002109A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridine
- treating cancer
- substituted pyrrolo
- modulators useful
- erbb
- Prior art date
Links
- -1 4-substituted pyrrolo[2,3-b]pyridine Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 101150029707 ERBB2 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a ciertos compuestos de 1H-pirrolo [2,3-b] piridina 4-sustituidos de fórmula (I) y sus sales farmacéuticamente aceptables del mismo. Estos compuestos son útiles en el tratamiento o prevención de una enfermedad o condición médica mediada a través de ciertas formas mutadas del receptor ErbB, especialmente de las mutaciones de Her2 y EGFR en el exón 20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18190603.3A EP3613738A1 (en) | 2018-08-23 | 2018-08-23 | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
PCT/EP2019/072564 WO2020039060A1 (en) | 2018-08-23 | 2019-08-23 | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002109A true MX2021002109A (es) | 2021-04-28 |
Family
ID=63442398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002109A MX2021002109A (es) | 2018-08-23 | 2019-08-23 | Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220370440A1 (es) |
EP (2) | EP3613738A1 (es) |
JP (1) | JP2022512536A (es) |
KR (1) | KR20210049096A (es) |
CN (1) | CN112585138A (es) |
AU (1) | AU2019324528A1 (es) |
BR (1) | BR112021002986A2 (es) |
CA (1) | CA3105010A1 (es) |
IL (1) | IL280661A (es) |
MX (1) | MX2021002109A (es) |
SG (1) | SG11202100126QA (es) |
WO (1) | WO2020039060A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3868759A1 (en) * | 2020-02-20 | 2021-08-25 | PearlRiver Bio GmbH | 2,3,5-substituted pyrrolo[2,3-b]pyridines as erbb modulators useful for treating cancer |
EP3868760A1 (en) * | 2020-02-20 | 2021-08-25 | PearlRiver Bio GmbH | 2,3,5-substituted pyrrolo[2,3-b]pyridines as erbb modulators useful for treating cancer |
WO2022033416A1 (zh) * | 2020-08-10 | 2022-02-17 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
WO2011075613A1 (en) * | 2009-12-18 | 2011-06-23 | Sanofi | Azaindole derivatives, their preparation and their therapeutic application |
KR101752519B1 (ko) * | 2010-03-22 | 2017-06-29 | 리드 디스커버리 센터 게엠베하 | 제약 활성 이치환된 트리아진 유도체 |
EP2802568A1 (en) * | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
RU2018104702A (ru) * | 2012-08-06 | 2019-02-22 | Ацея Байосайенсиз Инк. | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
US20170166598A1 (en) * | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
MX2017009571A (es) * | 2015-01-23 | 2018-09-27 | Aclaris Therapeutics Inc | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. |
CA2976227C (en) * | 2015-02-17 | 2023-10-24 | Neupharma, Inc. | Quinazoline derivatives and their use in treatment of cancer |
WO2017066193A1 (en) * | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
CN106946896B (zh) * | 2017-03-30 | 2019-05-21 | 成都知普莱生物医药科技有限公司 | 呋喃并[2,3-d]嘧啶-4-胺衍生物 |
-
2018
- 2018-08-23 EP EP18190603.3A patent/EP3613738A1/en not_active Withdrawn
-
2019
- 2019-08-23 CN CN201980055136.3A patent/CN112585138A/zh active Pending
- 2019-08-23 JP JP2021510184A patent/JP2022512536A/ja active Pending
- 2019-08-23 WO PCT/EP2019/072564 patent/WO2020039060A1/en unknown
- 2019-08-23 SG SG11202100126QA patent/SG11202100126QA/en unknown
- 2019-08-23 AU AU2019324528A patent/AU2019324528A1/en not_active Abandoned
- 2019-08-23 BR BR112021002986-9A patent/BR112021002986A2/pt not_active Application Discontinuation
- 2019-08-23 CA CA3105010A patent/CA3105010A1/en active Pending
- 2019-08-23 MX MX2021002109A patent/MX2021002109A/es unknown
- 2019-08-23 EP EP19769018.3A patent/EP3807274B1/en active Active
- 2019-08-23 US US17/270,221 patent/US20220370440A1/en active Pending
- 2019-08-23 KR KR1020217004573A patent/KR20210049096A/ko unknown
-
2021
- 2021-02-04 IL IL280661A patent/IL280661A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210049096A (ko) | 2021-05-04 |
US20220370440A1 (en) | 2022-11-24 |
SG11202100126QA (en) | 2021-02-25 |
AU2019324528A1 (en) | 2021-01-28 |
EP3807274B1 (en) | 2022-07-27 |
EP3807274A1 (en) | 2021-04-21 |
IL280661A (en) | 2021-03-25 |
CN112585138A (zh) | 2021-03-30 |
EP3613738A1 (en) | 2020-02-26 |
CA3105010A1 (en) | 2020-02-27 |
JP2022512536A (ja) | 2022-02-07 |
WO2020039060A1 (en) | 2020-02-27 |
BR112021002986A2 (pt) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107548391A8 (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
MX2021002109A (es) | Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer. | |
PH12015501326A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | |
AU2020255100A8 (en) | N-heteroaromatic amide derivatives for treatment of cancer | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
NZ627900A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
TN2010000040A1 (en) | 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases | |
WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
MX2021001690A (es) | Indoles sustituidos y metodos de uso de los mismos. | |
MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
TW200519104A (en) | Quinazoline derivatives | |
MY192029A (en) | 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
MX2021009743A (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. | |
MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
PH12021550242A1 (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
PH12019501968A1 (en) | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
HK1132273A1 (es) | ||
TW200640904A (en) | Quinazoline derivatives | |
WO2022076831A3 (en) | Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer | |
EA202092034A2 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака |